Dr Jean-Pierre Bourquin talks to ecancer at the European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia about the use of novel functional assays to evaluate a patient's drug response.
He discusses the functionality of these assays, which include identifying the sensitivity and resistance profiles of a patient's leukaemia cells.
Dr Bourquin concludes by stating that patient subsets need more precise interrogation and an improved regulatory framework for clinical trials in this disease type.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.